A combination of two Bristol-Myers Squibb immuno-oncology agents—Opdivo (nivolumab) and Yervoy (ipilimumab)—received an accelerated approval for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
The Centers for Medicare and Medicaid Services appear to be executing a two-step strategy to shrink the $8 billion annual price tag of clinical diagnostic laboratory tests.
THE CENTER TO ADVANCE PALLIATIVE CARE and National Palliative Care Research Center published a state-by-state report card evaluating access to palliative care.
A STAND UP TO CANCER CANADA DREAM TEAM researching approaches to treating triple-negative breast cancer and other aggressive types of breast cancer has been formed following a $9 million investment from a coalition of funders.
JAN SCHLÜCHTER was named chief commercial officer of Myriad Genetics GmbH, effective Oct. 15.
KIRAN TURAGA was named the Sharon K. Wadina Endowed Professor in Sarcoma Research at the Medical College of Wisconsin.
JAMES WADE was named deputy director for quality and network development at the Inova Dwight and Martha Schar Cancer Institute.
SANTOSH KESARI joined the Providence Saint John's Health Center and its John Wayne Cancer Institute.
THREE INVESTIGATORS were named recipients of the 2015 Paul Marks Prize for Cancer Research by Memorial Sloan Kettering Cancer Center. The award recognizes investigators age 45 or younger for their efforts in advancing cancer research.
City of Hope and Sorrento Therapeutics Inc. formed a company, LA Cell Inc., to focus on the development of cell-penetrating antibody therapies. LA Cell has exclusively licensed technology developed at City of Hope that enables modified monoclonal antibodies to penetrate into cells and target disease-causing molecules.
